Marquardt C, Tolstik T, Bielecki C, Kaufmann R, Crecelius A C, Schubert U S, Settmacher U, Stallmach A, Dirsch O
Department of InternaI Medicine IV, Gastroenterology, Hepatology and Infectious Diseases, Jena University Hospital, Jena.
Experimental Transplantation Surgery, Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena.
Z Gastroenterol. 2015 Jan;53(1):33-9. doi: 10.1055/s-0034-1385398. Epub 2015 Jan 16.
Histopathologic differentiation of nodular lesions in cirrhotic liver is difficult even for experienced hepatopathologists especially regarding diagnosis of hepatocellular carcinoma (HCC) in biopsies. For this reason, new tissue markers are needed to reinforce histopathologic decision-making. With advances in molecular techniques, proteomic analysis may help to confirm the diagnosis of HCC. Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is a powerful technology which allows to determine and to localize proteins directly in tissue sections. Using MALDI IMS proteomic patterns of cryosections with lesions of HCC (n = 15) and non-malignant fibrotic liver tissue (n = 11) were investigated to establish a classification model of HCC, which was validated in an independent set of tissue to distinguish HCC (n = 10) from regenerative nodules (n = 8). By correlating generated mass spectrometric images with the histology of the tissue sections we found that the expression of 4 proteins as indicated by m/z 6274, m/z 6647, m/z 6222 and m/z 6853 was significantly higher in HCC tissue than in non-tumorous liver tissue. The generated classification model based on the most significant 3 differentially expressed proteins allowed a reliable prediction of benign and malignant lesions in fibrotic liver tissue with a sensitivity and specificity of 90 % in the validation set. The identified MALDI IMS proteomic signature can be diagnostically helpful to allow simplifying the diagnostic process and minimize the risks of delays in establishing the objective final diagnosis and initiating treatment of patients with HCC.
即使对于经验丰富的肝脏病理学家而言,肝硬化肝脏中结节性病变的组织病理学鉴别也很困难,尤其是在活检中诊断肝细胞癌(HCC)。因此,需要新的组织标志物来加强组织病理学决策。随着分子技术的进步,蛋白质组分析可能有助于确诊HCC。基质辅助激光解吸/电离成像质谱(MALDI IMS)是一项强大的技术,可直接在组织切片中确定和定位蛋白质。利用MALDI IMS研究了HCC病变(n = 15)和非恶性纤维化肝组织(n = 11)的冷冻切片的蛋白质组模式,以建立HCC的分类模型,并在一组独立的组织中进行验证,以区分HCC(n = 10)和再生结节(n = 8)。通过将生成的质谱图像与组织切片的组织学相关联,我们发现m/z 6274、m/z 6647、m/z 6222和m/z 6853所示的4种蛋白质在HCC组织中的表达明显高于非肿瘤性肝组织。基于最显著的3种差异表达蛋白质生成的分类模型能够可靠地预测纤维化肝组织中的良性和恶性病变,在验证集中的敏感性和特异性为90%。所确定的MALDI IMS蛋白质组特征在诊断上可能有所帮助,有助于简化诊断过程,并将延迟确立客观最终诊断和启动HCC患者治疗的风险降至最低。